RCKT stock forecast, quote, news & analysis
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company... Show more
Why Rocket Pharmaceuticals (RCKT) Stock Is Down 31% in the Last 30 Days
Key Takeaways
- Rocket Pharmaceuticals (RCKT) shares have declined roughly 31% over the past 30 days, falling from about $3.37 to near $2.33.
- The decline has persisted despite FDA alignment on the pivotal Phase 2 trial of RP-A501 in Danon disease and updated clinical data presented at an October investor webinar.
- Investor sentiment has been weighed down by an extended development timeline, with pivotal dosing completion targeted for mid-2027 and topline data anticipated in mid-2028.
- Analyst views remain mixed: Goldman Sachs upgraded the stock to Neutral from Sell with a $4 price target, while Cantor Fitzgerald and Bank of America maintained Buy ratings.
- The company strengthened its balance sheet with a credit facility of up to $150 million from Hercules Capital, providing non-dilutive capital for its cardiovascular pipeline.
Rocket Pharmaceuticals (RCKT) Company Overview and Market Position
Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) is a fully integrated, commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases, with a strategic focus on inherited cardiovascular disorders and additional programs in hematology and immunology. Its cardiovascular portfolio includes three clinical-stage gene therapy programs targeting hypertrophic, arrhythmogenic, and dilated cardiomyopathies, representing one of the broadest pipelines dedicated to inherited heart disease.
The company's lead candidate, RP-A501, is an investigational AAV-based gene therapy for Danon disease, a rare X-linked disorder that frequently leads to heart failure and early death. Rocket also holds a commercial-stage asset in Kresladi (marnetegragene autotemcel), which received FDA accelerated approval for severe leukocyte adhesion deficiency-I (LAD-I), and benefits from proprietary adeno-associated virus (AAV) manufacturing capabilities. Investors follow RCKT closely because its pipeline addresses significant unmet medical needs in cardiac gene therapy, an area with limited treatment options.
Rocket Pharmaceuticals (RCKT) Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, RCKT has fallen approximately 31%, declining from a closing level of about $3.37 to near $2.33. The move reflects sustained selling pressure rather than a single-day event, with the stock trending lower through late September and into October despite a series of corporate and clinical updates.
The broader multi-month trend tells a similar story. Over the last quarter, the stock has shed roughly 32%, retreating from levels near $3.40 in late July. After trading in a range around the mid-$3 to near $4 area during August and early September, RCKT broke lower and has remained under pressure, underscoring a cautious posture among investors toward the company's extended clinical timelines and near-term commercial outlook.
What Drove RCKT Stock Price in the Last 30 Days
Several factors shaped RCKT's recent price action. On September 15, Rocket announced alignment with the U.S. FDA on the path to completing the pivotal Phase 2 trial of RP-A501 in Danon disease, including a 12-patient efficacy population and established co-primary endpoints intended to support a potential accelerated approval. While a milestone, the update also reinforced a longer road ahead: Rocket expects to complete dosing by mid-2027, with topline results anticipated in mid-2028.
In early October, the company hosted a Danon disease investor webinar detailing updated clinical findings. Longer-term Phase 1 data showed sustained biological activity, with all six principal patients demonstrating myocardial LAMP2 protein expression and a reduction in left ventricular mass index, while initial safety observations from the first three patients treated under a modified protocol showed no evidence of thrombotic microangiopathy or capillary leak syndrome. Despite these encouraging data points, the extended timeline to pivotal results has tempered enthusiasm.
On the financing front, Rocket secured a credit facility of up to $150 million from Hercules Capital (HTGC) to support its cardiovascular strategy, a non-dilutive move that strengthened its balance sheet. Around the same time, Goldman Sachs upgraded RCKT to Neutral from Sell with a price target of $4, citing improved visibility into RP-A501's clinical and regulatory path, though the firm remained cautious on the drug's commercial potential. Cantor Fitzgerald reiterated a Buy rating with a $15 target, while Morgan Stanley maintained a Hold rating, reflecting a wide divergence in views on the stock's risk-reward profile.
What Drove RCKT Stock Performance Over the Last Quarter
The quarterly decline reflects a broader reassessment of Rocket's pipeline execution and commercial trajectory. Earlier in 2026, the company transitioned to commercial-stage status following the FDA's accelerated approval of Kresladi for LAD-I, but shares sold off as investors focused on the therapy's limited patient population and the company's phased launch plans rather than a broad marketing push. Rocket subsequently monetized a Rare Pediatric Disease Priority Review Voucher for $180 million to bolster its cash position.
At the same time, the market has continued to weigh the long timelines inherent to cardiovascular gene therapy development. While Rocket has demonstrated durable biological activity in early Danon disease studies, the path to pivotal data extends into 2028, leaving the stock sensitive to sentiment shifts and funding considerations. Broader pressures in the small-cap biotechnology space and index-related dynamics have also contributed to the stock's persistent underperformance during the period.
Trending AI Robots
For traders seeking a data-driven approach to market opportunities, Tickeron's Trending AI Robots page offers a curated view of its most relevant AI trading bots. Tickeron provides hundreds of AI-powered trading bots that trade across thousands of tickers, but only the top-performing and most relevant bots appear in this dedicated section. These bots vary in strategy, timeframe, and performance metrics, allowing users to explore approaches that align with different trading styles and objectives. Whether you are monitoring momentum, trend reversals, or broader market patterns, the section offers a convenient starting point for discovering automated strategies. Explore the Trending AI Robots page to see which strategies are currently attracting attention.
RCKT Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on several key catalysts. The most significant is continued execution of the pivotal Phase 2 trial of RP-A501, including patient enrollment progress, additional safety data from the modified protocol, and any further regulatory alignment updates. Near-term clinical milestones across the broader cardiovascular pipeline, including the RP-A601 and RP-A701 programs, will also be closely monitored.
On the commercial side, the initial launch trajectory of Kresladi and the company's ability to secure reimbursement at specialized treatment centers remain important. Financial health is another consideration, given the cash runway and the recent credit facility. Finally, broader macroeconomic conditions, interest-rate dynamics, and sentiment toward clinical-stage biotechnology and small-cap stocks could continue to influence RCKT's valuation independent of company-specific news. Investors should weigh these factors carefully and consider their own risk tolerance, as clinical and regulatory outcomes remain inherently uncertain.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RCKT in downward trend: 10-day moving average broke below 50-day moving average on September 21, 2026
The 10-day moving average for RCKT crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for RCKT entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RCKT's RSI Indicator exited the oversold zone, 33 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for RCKT just turned positive on October 20, 2026. Looking at past instances where RCKT's MACD turned positive, the stock continued to rise in 45 of 52 cases over the following month. The odds of a continued upward trend are 87%.
Following a +7.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in 204 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RCKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.696) is normal, around the industry mean (3.009). P/E Ratio (-14.625) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. RCKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of gene therapy services
Industry Biotechnology